RecruitingNCT06708507

Tissue-resident Immune Cell Subsets in aGVHD

A Prospective Study on the Correlation Between Tissue-resident Immune Cell Subsets and Graft-versus-host Disease Following Hematopoietic Stem Cell Transplantation.


Sponsor

Nanfang Hospital, Southern Medical University

Enrollment

40 participants

Start Date

Nov 16, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This is a prospective study investigating the role of tissue-resident immune cell subsets in the occurrence and progression of graft-versus-host disease following hematopoietic stem cell transplantation. Approximately 40 subjects(including 20 grade 3-4 aGVHD patients and 20 grade 1-2 aGVHD patients ).


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Inclusion Criteria3

  • Voluntarily sign the informed consent form;
  • Age 16-65 years old
  • Clinically diagnosed with GVHD for the first time/receiving GVHD treatment.

Exclusion Criteria6

  • Have a history of other tumors
  • With poor compliance or mental disorders
  • Infected with HIV and HCV
  • With uncontrolled HBV infection
  • With other autoimmune diseases
  • Those who are judged by the researcher to be unsuitable to participate in this study

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Nanfang Hospital, Southern Medical University

Guangzhou, Other (Non U.s.), China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06708507


Related Trials